Last reviewed · How we verify
NCT06762470
Prognostic Value of CD4/CD8 Ratio in Patients with Nasopharyngeal Carcinoma
trial in Histopathological Diagnosis of Nasopharyngeal Carcinoma in 325 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2028
Quick facts
| Lead sponsor | Jiangxi Provincial Cancer Hospital |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 325 |
| Start date | 1 January 2025 |
| Primary completion | 31 December 2028 |
| Estimated completion | 31 December 2029 |
| Sites | 1 location across China |
Conditions studied
- Histopathological Diagnosis of Nasopharyngeal Carcinoma — all drugs for Histopathological Diagnosis of Nasopharyngeal Carcinoma →
- Patients with Nasopharyngeal Carcinoma Without Distant Metastases After AJCC/UACC 8th Edition — all drugs for Patients with Nasopharyngeal Carcinoma Without Distant Metastases After AJCC/UACC 8th Edition →
Sponsor
Jiangxi Provincial Cancer Hospital
Who can join
Adults 18 to 70, any sex, with Histopathological Diagnosis of Nasopharyngeal Carcinoma or Patients with Nasopharyngeal Carcinoma Without Distant Metastases After AJCC/UACC 8th Edition. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In our previous retrospective study, we identified circulating immune cell counts and the CD4/CD8 ratio as significant prognostic markers in nasopharyngeal carcinoma. Building on these findings, this study aims to conduct a multi-center prospective observational study to evaluate the prognostic value of the circulating lymphocyte CD4/CD8 ratio in nasopharyngeal carcinoma patients prior to treatment.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Prognostic Significance of Circulating Immune Subset Counts in Nasopharyngeal Carcinoma.
Xie H, Zhang L, Chen L, Zhou W, et al · · 2025 · cited 1× · PMID 40546336 · DOI 10.2147/itt.s516853
Verify or expand the search:
- PubMed search for NCT06762470
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Jiangxi Provincial Cancer Hospital trials
Trials by the same sponsor.
- NCT07314255 — The Role of Trop2 in Radioactive Iodine-131 Therapy Sensitivity in Papillary Thyroid Carcinoma · active not recruiting
- NCT07277764 — Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carc · Phase 2 · recruiting
- NCT06752239 — Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC · Phase 3 · recruiting
- NCT07085988 — Effect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma · Phase 2 · recruiting
- NCT06770699 — Tertiary Lymphoid Structures in Nasopharyngeal Carcinoma · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06762470 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jiangxi Provincial Cancer Hospital
- Last refreshed: 9 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06762470.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing